Corey Cutler, MD, MPH, medical director of the Adult Stem Cell Transplantation Center at Dana-Farber Cancer Institute, discusses Blood and Marrow Clinical Trials Network Study 1102, comparing patients aged 50–75 with advanced myelodysplastic syndrome who were matched with a stem cell transplant donor and those who did not receive transplant. After three years, individuals with donors achieved around 50% survival, while those with no donor had approximately 30% survival. Dr. Cutler hopes to see more patients referred early on for transplantation to enhance chances of receiving stem cell transplants.